Revance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($0.81), $0.20 better than the analyst estimate of ($1.01). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $90 thousand.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.